GSMA
6.6.2018 10:02:09 CEST | Business Wire | Press release
As part of its role within the W20 (Women 20) group1 , the GSMA has backed a series of recommendations to promote digital inclusion for women to be presented to the G20 member states later this year. The GSMA is Topic Chair of the Digital Inclusion theme within the W20, which is advising the G20 on issues around gender equality and the economic empowerment of women, supporting the Sustainable Development Goals (SDGs), particularly SDG #5 (Gender Equality).
“The GSMA has been privileged to help shape the W20 recommendations, which will provide an actionable roadmap for the G20 nations to drive gender equality policies around the world,” said Mats Granryd, Director General of the GSMA. “These recommendations underline the importance of closing the digital gender gap by removing barriers to access and use, and promoting policies that encourage the digital inclusion of women. We believe this approach will ensure women and girls play a major role in shaping our future digital economies.”
“Ensuring that women are digitally included brings significant benefits for them and for their communities and economies”, added Susana Balbo, Chair of the W20.
At a W20 roundtable in Paris last week, the GSMA chaired the debate between the W20 delegates to set the Digital Inclusion recommendations. There are four agreed recommendations that call on G20 member states to:
1) Collect, track and analyse data on women’s access to and use of digital technologies and on the presence of women in STEM-related courses, careers and in leadership positions;
2) Develop holistic policies that focus on the barriers to women’s access to and use of digital technologies including accessibility, affordability, safety and security, digital skills and availability of relevant content and services;
3) Promote initiatives that drive equal participation of women and girls in STEM studies and digital-intensive work to ensure that women participate and lead in the design, development and governance of digital technologies, as well as entrepreneurs in the digital sector;
4) Ensure that all analyses of the future of work, including education needs and demands for new skills, are performed with a view to gender balance, social protection and job quality.
These recommendations feed into what will be presented at the G20 Argentina 2018 summit taking place in Buenos Aires, 30 November – 1 December 2018, where the G20 governments will be asked to make concrete commitments on each issue.
Mobile Industry Supporting Digital Inclusion for Women
The
GSMA is committed to supporting increased digital and financial
inclusion for women, reflecting the fact that mobile is the primary way
for people to access the internet in many parts of the world. However,
according to the latest GSMA research2
, women in low- and
middle-income countries are 26 percent less likely than men to use
mobile internet.
As part of the GSMA’s Connected Women initiative, 36 mobile operators across Africa, Asia and Latin America have made 51 formal commitments to reduce the gender gap in their mobile money or mobile internet customer base, driving an effort to accelerate digital and financial inclusion for women. To date, the Connected Women programme and its mobile operator partners have delivered life-enhancing services to more than 22 million women.
As well as the Connected Women programme and its participation in W20 , the GSMA also supports efforts to accelerate digital and financial inclusion for women via its participation in W20 ; the EQUALS initiative; the GSMA Connected Women programme; Women4Tech ; the WeCare initiative in Latin America; and the #BetterFuture campaign.
-ENDS-
About the GSMA
The GSMA represents the interests of mobile
operators worldwide, uniting nearly 800 operators with more than 300
companies in the broader mobile ecosystem, including handset and device
makers, software companies, equipment providers and internet companies,
as well as organisations in adjacent industry sectors. The GSMA also
produces industry-leading events such as Mobile World Congress, Mobile
World Congress Shanghai, Mobile World Congress Americas and the Mobile
360 Series of conferences.
For more information, please visit the GSMA corporate website at www.gsma.com . Follow the GSMA on Twitter: @GSMA .
________________________
1
The W20 is one of seven
independent engagement groups comprised of civil society organisations
from the G20 member counties. The engagement groups convene in tandem
with the G20 and ensure that the position of civil society on important
issues is taken on board by the G20 leaders. For more information see http://w20argentina.com
2
https://www.gsma.com/mobilefordevelopment/programmes/connected-women/the-mobile-gender-gap-report-2018
View source version on businesswire.com: https://www.businesswire.com/news/home/20180606005078/en/
Contact:
For the GSMA
Beau Bass
+44 79 7662 4962
beau.bass@webershandwick.com
or
GSMA
Press Office
pressoffice@gsma.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
